Which disease is Platinib mainly used to treat?

Pralsetinib (Pralsetinib) is an effective oral drug that is a selective RET kinase inhibitor for the treatment of rearrangement during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) and RET-mutated medullary thyroid cancer (MTC). Platinib is indicated for the treatment of the following conditions:

1. Adult patients with non-small cell lung cancer (NSCLC) who are positive for metastatic rearrangement during transfection (RET) fusion as detected by a U.S. Food and Drug Administration (FDA)-approved test.

2. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine therapy (if radioactive iodine is applicable).

The active substance in pralsetinibpralsetinib is a RET inhibitor and belongs to the tyrosine kinase inhibitor class of anti-cancer drugs. It blocks the activity of an abnormal protein called a RET fusion protein, which is produced by the body as a result of changes in the RET gene. In non-small cell lung cancer and thyroid cancer cells, RET fusion proteins can lead to uncontrolled cell growth and cancer. By blocking the RET fusion protein, Platinib helps reduce the growth and spread of cancer.

Platinib is in capsule form, and the recommended dosage regimen is to take 400 mg daily It is best to take it on an empty stomach with a glass of water. This medicine is a prescription medicine and must be used under the guidance of a doctor. To ensure treatment efficacy and safety, patients should strictly abide by medical instructions and take the recommended dose at a fixed time every day without overdosing or reducing the dose. If vomiting occurs after taking the medicine, there is no need to take a supplementary dose, just continue taking the medicine according to the original plan.